Targeting heart failure with preserved ejection fraction: current status and future prospects.
Targeting heart failure with preserved ejection fraction: current status and future prospects.
复制标题
DOI：
10.2147/vhrm.s83662
复制
发表时间：
2016
影响因子：
2.9
通讯作者：
Patarroyo-Aponte M
中科院分区：
文献类型：
--
作者：
Kanwar M;Walter C;Clarke M;Patarroyo-Aponte M
射血分数正常的心力衰竭（HFpEF）在患病率、发病率、死亡率和医疗保健费用方面造成了重大负担。目前对该综合征的基本病理生理学、定义和治疗靶点缺乏共识。到目前为止，还没有批准的治疗方法可用于降低这些患者的死亡率或住院率。一些临床试验最近开始尝试弥合这一重大差距。目前迫切需要关注HFpEF的药物和器械开发以及了解HFpEF的病理生理学。
Heart failure with preserved ejection fraction (HFpEF) portrays a significant burden in terms of prevalence, morbidity, mortality, and health care costs. There is a lack of consensus on the basic pathophysiology, definition, and therapeutic targets for therapy for this syndrome. To date, there are no approved therapies available for reducing mortality or hospitalization for these patients. Several clinical trials have recently started to try and bridge this major gap. There is an urgent need to focus on drug and device development for HFpEF as well as to understand HFpEF pathophysiology.